Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

Journal of Medicinal Chemistry

Volumn 39, Issue 15, 1996, Pages 3019-3029

  Naito, Youichiro ^a   Akahoshi, Fumihiko ^a   Takeda, Shinji ^a   Okada, Takehiro ^a   Kajii, Masahiko ^a   Nishimura, Hiroko ^a   Sugiura, Masanori ^a   Fukaya, Chikara ^a   Kagitani, Yoshio ^a  

^a Green Cross Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 5 AMINO 3 (4 CHLOROPHENYL) 1 [(METHYLAMINO)THIOCARBONYL] 1H 1,2,4 TRIAZOLE; ALLERGEN; ANTIASTHMATIC AGENT; APAFANT; GINKGOLIDE B; INTERLEUKIN 5; LEUKOTRIENE D4; PROSTAGLANDIN SYNTHASE INHIBITOR; SEPHADEX; THROMBOCYTE ACTIVATING FACTOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHRONIC DISEASE; DRUG MECHANISM; DRUG SYNTHESIS; EOSINOPHILIA; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIGENS, HELMINTH; ASCARIS; CELL SURVIVAL; DEXAMETHASONE; DEXTRANS; EOSINOPHILIA; EOSINOPHILS; GUINEA PIGS; HUMANS; INTERLEUKIN-5; MALE; MOLECULAR STRUCTURE; PULMONARY EOSINOPHILIA; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RESPIRATORY HYPERSENSITIVITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 0029943547     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9507993     Document Type: Article

References (43)

1. (a) Gleich, G. J. The eosinophil and bronchial asthma: current understanding. J. Allergy Clin. Immunol. 1990, 85, 422-36.
2. (b) Reed, C. E. The importance of eosinophils in the immunology of asthma and allergic disease. Ann. Allergy 1994, 72, 376-380.
3. De Monchy, J. G. R.; Kauffman, H. F.; Venge, P.; Koeter, G. H.; Jansen, H. M.; Sluiter, H. J.; De, V. K Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis. 1985, 131, 373-6.
4. +) T cells and eosinophils in allergy and asthma. Am. Rev. Respir. Dis. 1992, 145, s22-6.
5. Corrigan, C. J.; Kay, A. B. T cells and eosinophils in the pathogenesis of asthma. Immunol. Today 1992, 13, 501-7.
6. Van Oosterhout, A. J. M.; Van Der Poel, A.; Koenderman, L.; Roos, D.; Nijikamp, F. P. Interleukin-5 potentiates sulfidepeptide leukotriene production by human eosinophils. Mediat. Inflamm. 1994, 3, 53-55.
7. (a) Paliogianni, F.; Ahuja, S. S.; Balow, J. P.; Balow, J. E.; Boumpas, D. T. Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor. J. Immunol. 1993, 151, 4081-9.
8. (b) Elwood, W.; Lotvall, J. O.; Barnes, P. J.; Chung, K. F. Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. Am. Rev. Respir. Dis. 1992, 145, 1289-94.
9. Silva, P. M. R.; Martins, M. A.; Lima, M. C.; Alves, A. C.; Diaz, B. L.; Cordeiro, R. S. Pharmacological modulation of the late eosinophilia induced by antigen in actively sensitized rats. Int. Arch. Allergy Immunol. 1992, 98, 355-60.
10. Elwood, W. E.; Sun, J.; Barnes, P. J.; Giembycz, M. A.; Chung, K. F. Inhibition of allergene-induced lung eosinophilia by type-III and combined type III- and IV-selective Phosphodiesterase inhibitors on Brown-Norway rats. Inflamm. Res. 1995, 44, 83-86.
11. (a) Spicer, B. A.; Baker, R. C.; Hatt, P. A.; Laycock, S. M.; Smith, H. The effects of drugs on Sephadex-induced eosinophilia and lung hyper-responsiveness in the rat. Br. J. Pharmacol. 1990, 101, 821-8.
12. (b) Laycock, S. M.; Smith, H.; Spicer, B. A. Airway hyper-reactivity and blood, lung and airway eosinophilia in rats treated with Sephadex particles. Int. Arch. Allergy Appl. Immunol. 1986, 81, 363-7.
13. (c) Spicer, B. A.; Baker, R.; Laycock, S. M.; Smith, H. Correlation between blood eosinophilia and airways hyper-responsiveness in rats. Agents Actions 1989, 26, 63-5.
14. (d) Cook, R. M.; Musgrove, N. R.; Smith, H. Eosinophils and the granulomatous reaction in rats injected with Sephadex particles. Pulm. Pharmacol. 1989, 2, 185-90.
15. Akahoshi, F.; Okada, T.; Takeda, S.; Naito, Y.; Fukaya, C.; Kuwahara, S.; Kajii, M.; Nishimura, H.; Sugiura, M. Triazole derivative and pharmacological thereof. W095/03286, 1995; Chem. Abstr. 1995, 123, 256720.
16. Hirata, T.; Twanmoh, L.; Wood, H. B.; Goldin, A.; Driscoll, J. S. 5-Azapurines and the structures of sym-triazole intermediates. J. Heterocycl. Chem. 1972, 9, 99-106.
17. Hodgkins, J. E.; Reeves, W. P. The modified kaluza synthesis III. The synthesis of some aromatic isothiocyanates. J. Org. Chem. 1964, 29, 3098-3099.
18. Meyer, R. F.; Cummings, B. L.; Bass, P.; Collier, H. O. J. Synthesis and pharmacological action of 3-amino-2,1-benzothiazoles. J. Med. Chem. 1968, 8, 515-519.
19. Cava, M. P.; Levinson, M. I. Thionation reactions of Lawesson's reagents. Tetrahedron 1985, 41, 5061-5087.
20. Boots, M. R.; Boots, S. G.; Moreland, D. E. Conformational aspects of ureas in the inhibition of the Hill reaction. J. Med. Chem. 1970, 13, 1414.
21. Nakadate, M.; Takano, Y.; Hirayama, T.; Sakaizawa, S.; Hirano, T.; Okamoto, K.; Hirao, K.; Kawamura, T.; Kimura, M. Janovsky reaction of nitropyridines. II. Preparation of 5-nitronicotinic acid and its related comounds. Chem. Pharm. Bull. 1965, 13, 113-118.
22. (a) Heitke, B. T.; McCarty, C. G. Syntheses of C-amino and C-Azide-1,2,4-triazoles. J. Org. Chem. 1974, 39, 1522-1526.
23. (b) Huffman, K. R.; Schaefer, F. C. N-Cyanoimidates. J. Org. Chem. 1963, 28, 1816-1821.
24. Wright, J. B.; Hall, C. M.; Johnson, H. G. N,N′-(Phenylene)-dioxamic acids and their esters as antiallergy agents. J. Med. Chem. 1978, 27, 930-5.
25. 2-receptor antagonists. J. Med. Chem. 1985, 28, 1628-36.
26. Mullican, M. D.; Wilson, M. W.; Connor, D. T.; Kostlan, C. R.; Schrier, D. J.; Dyer, R. D. Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents. J. Med. Chem. 1993, 36, 1090-9.
27. Yamada, N.; Ohgaki, M.; Muramatsu, M. Antigen-induced airway hyperresponsiveness is associated with infiltration of eosinophils in lung tissue, but not with bronchoalveolar lavage eosinophilia or neutrophilia. Int. Arch. Allergy Immunol. 1994, 103, 73-8.
28. Sanjar, S.; Aoki, S.; Boubekeur, K.; Burrows, L.; Colditz, I.; Chapman, I.; Morley, J. Inhibition of PAF-induced eosinophil accumulation in pulmonary airways of guinea pigs by antiasthma drugs. Jpn. J. Pharmacol. 1989, 51, 167-72.
29. Kuitert, L. M.; Hui, K. P.; Uthayarkumar, S.; Burke, W.; Newland, A. C.; Uden, S.; Barnes, N. C. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am. Rev. Respir. Dis. 1993, 147, 82-83.
30. Cook, R. M.; Musgrove, N. R.; Smith, H. Eosinophils and the granulomatous reaction in rats injected with Sephadex particles. Pulm. Pharmacol. 1989, 2, 185-90.
31. Basten, A.; Boyer, M. H.; Beeson, P, B. Mechanism of eosinophilia. I. Factors affecting the eosinophil response of rats to Trichinella spiralis. J. Exp. Med. 1970, 131, 1271-87.
32. Walls, R. S.; Beeson, P. B. Mechanism of eosinophilia. IX. Induction of eosinophilia in rats by certain forms of dextran. Proc. Soc. Exp. Biol. Med. 1972, 140, 689-93.
33. Sorden, S. D.; Lemanske, R. J.; Castleman, W. L. Pulmonary eosinophilia and granulomatous pulmonary arteritis induced in rats by intravenous Sephadex. Vet. Pathol. 1990, 27, 217-22.
34. Das, A. M.; Williams, T. J.; Lobb, R.; Nourshargh, S. Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model. Immunology 1995, 84, 41-6.
35. Data was obtained from the NOESY mesurement.
36. (a) Topliss, J. G. Utilization of operational schemes for analog synthesis in drug design. J. Med. Chem. 1972, 15, 1006-11.
37. (b) Topliss, J. G. A manual method for applying the Hansch approach to drug design. J. Med. Chem. 1977, 20, 463-9.
38. Inoue, H.; Aratani, H.; Takishima, T.; Kagoshima, M.; Iwahisa, Y.; Terasawa, M. Effect of a potent PAF antagonist, Y-24180, on an allergen-induced late asthmatic response in guinea-pigs. J. Lipid Mediat. 1992, 5, 173-6.
39. (a) Tahraoui, L.; Floch, A.; Cavero, I. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets. J. Pharmacol. Exp. Ther. 1990, 252, 1221-7.
40. (b) Hwang, S. B.; Lam, M. H.; Shen, T. Y. Specific binding sites for platelet activating factor in human lung tissues. Biochem. Biophys. Res. Commun. 1985, 128, 972-9.
41. Weichman, B. M.; Wasserman, M. A.; Holden, D. A.; Osborn, R. R.; Woodward, D. F.; Ku, T. W.; Gleason, J. G. Antagonism of the pulmonary effects of the peptidoleukotrienes by a leukotriene D4 analog. J. Pharmacol. Exp. Ther. 1983, 227, 700-5.
42. Sugiura, M.; Naito, Y.; Yamaura, Y.; Fukaya, C.; Yokoyama, K. Inhibitory activities and inhibition specificities of caffeic acid derivatives and related compounds toward 5-lipoxygenase. Chem. Pharm. Bull. Jpn. 1989, 37, 1039-43.
43. Wallen, N.; Kita, H.; Weiler, D.; Gleich, G. J. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J. Immunol. 1991, 147, 3490-5.